

**DBT Sponsered Two Days National Conference on
A Paradigm Shift for Emerging Paraphernalia in
Advancement of Cancer Research**

28 and 29 Feb-2020

DOI: <https://doi.org/10.37022/WJCMPR.2020.SC1>

Organized By



Nirmala College of Pharmacy

Affiliated to Kerala University of Health Sciences Thrissur

Approved By Government of Kerala, PCI and AICTE

Nirmala College Rd, Kizhakkekara, Muvattupuzha, Kerala 686661

TOXICITY PROFILE OF MULTIPLE MYELOMA PATIENTS TREATED WITH DIFFERENT THERAPEUTIC REGIMENS

Helan Kurian*¹; Suja Abraham²; Jeeva Ann Jiju³; Timy Thomas⁴; Arpith Antony⁵

Nirmala College of Pharmacy, Muvattupuzha.

Abstract

Background: Multiple myeloma (MM) is a neoplasm of the plasma cells that affects approximately 6.5 / 1,00,000 and is the second most common haematological malignancy. Pharmacologically MM is managed by targeted therapy, chemotherapy, steroids, and stem cell transplantation. Choice of regimen depends on the baseline characteristics and progression stage. However, increased toxic events can decrease the prognosis

Objective: To study the toxicity profile of multiple myeloma patients treated with different therapeutic regimens.

Methodology: 45 patients with newly diagnosed MM from a multi – specialty hospital from 2015 to 2019 were retrospectively analyzed. MM patients completed the regimens (Lenalidomide and Dexamethasone – RD, cyclophosphamide, bortezomib and dexamethasone – CyBorD; bortezomib and dexamethasone – BD; Thalidomide and Dexamethasone – TD, bortezomib, lenalidomide and dexamethasone – VRD) and follow up of at least 6 months were selected. Toxicity profile was categorized by using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

Results: A total of 293 toxicity events were found. Toxicity profile of TD, BD, VRD, RD and CyBorD were 21.5%, 27.64%, 35.83% and 15.01% respectively. About 147 grade 1 toxicities, 92 grade 2 toxicities, 46 grade 3 toxicities and 8 grade 4 toxicities were identified. Among this, 209 were hematological, 43 were CNS, 39 were hepatobiliary and urinary system, and few other adverse effects noted were pedal edema, alopecia, cutaneous and skin infections.

Conclusion: The RD had comparatively greatest toxicity profile while CyBorD showed least toxicity profile. The study also pinpoints the need for systematic ADR profiling and follow-up in Cancer patients.

Keywords: Multiple myeloma, bortezomib, toxicity profile.

Corresponding Author:

helankurian11@gmail.com



THE USE OF ARTIFICIAL INTELLIGENCE IN CLINICAL DIAGNOSIS OF HEPARIN INDUCED THROMBOCYTOPENIA

Jaime Elizabeth Jose*, Sangeeth P,

Department of pharmacy practice, St. Josephs College of Pharmacy

Abstract

Heparin induced thrombocytopenia (HIT) is a life threatening condition due to immunemediated side effect of heparin. HIT must be suspected when a patient who is receiving heparin has a decrease in the platelet count, particularly if the fall is over 50% of the baseline count. Diagnosis of HIT needs both clinical and laboratory evaluation and remains a challenge. The combination of clinical findings, thrombocytopenia characteristics and laboratory studies of HIT antibodies help in diagnosing HIT. Artificial intelligence use in bayesian algorithm help in early detection of HIT. The bayesian algorithm for HIT incorporated 'four Ts' (4Ts) scoring and a stratified interpretation of an anti-PF4/H enzyme-linked immunosorbent assay (ELISA).

Objective: The use of artificial intelligence in clinical diagnosis of heparin induced Thrombocytopenia. Method The incorporation of artificial intelligence in interpreting early markers in HIT the 4Ts scoring (thrombocytopenia, timing of platelet count fall, Thrombosis or other sequelae. Other causes of thrombocytopenia) 0-3: Low probability 4-5: Intermediate probability 6-8: High probability of HIT helps as a tool. This scoring system help in initiating steps to prevent the incidence of HIT when the scoring is in the probable range and therapeutic management of the patient. Further laboratory tests like anti-PF4/H ELISA and serotonin release assay (SRA) can be done in the highly probable cases to confirm the diagnosis.

Conclusion: The incorporation of artificial intelligence would increase the monitoring on patients using heparin and decrease the incidence of heparin induced thrombocytopenia.

Keyword: HIT, artificial intelligence, diagnosis, bayesian algorithm.